MassBio CEO & President Kendalle Burlin O’Connell sat down with Congressman Jake Auchincloss (MA-04) for BiotechTV to discuss the federal policy landscape facing Massachusetts biotech and the national implications.
The conversation covers the industry’s economic footprint, how the U.S. is positioned against global competitors, and the Congressman’s case for steadier federal support of basic research. He also takes up a problem MassBio has been raising all year: early-stage clinical trials are increasingly starting outside the U.S., and the cost of engaging with FDA falls hardest on the small companies doing the earliest, riskiest science. The two also cover Alzheimer’s research and what it takes to keep early-stage innovation here.
Watch the full conversation below.
This interview originally appeared on BiotechTV.
Chapters (borrowed from BiotechTV)
- The economic impact of biotech – 1:28
- Global competition – 9:19
- FDA – 16:02
- Modernization of clinical trials – 21:11
- Alzheimer’s research – 22:54
- Early stage innovation – 25:41
- Closing ideas – 32:10
